Trial reportAntimicrobial agents and chemotherapy2019
Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure.
Trial report in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Pooled it
- Pharmacokinetics and optimized dosing of dispersible and non-dispersible levofloxacin formulations in young children.The Journal of antimicrobial chemotherapy · 2023Trial
- Population pharmacokinetics and exposure-response analysis of levofloxacin in Chinese pediatric patients with severe refractoryAntimicrobial agents and chemotherapy · 2026Article
- Fluoroquinolones for TB preventive treatment of contacts exposed to persons with multidrug-resistant TB: a systematic review and meta-analysis.IJTLD open · 2026Article
- Single Saliva Sample Model-Informed Precision Dosing of Levofloxacin for Multidrug-Resistant Tuberculosis.Clinical pharmacokinetics · 2026Article
- Experiences in dissemination of results of a community-based tuberculosis prevention trial in children.Trials · 2026Article
- Deriving Dosages for Levofloxacin Tuberculosis Preventive Treatment for Young People Exposed to Rifampicin-Resistant Tuberculosis.The Journal of infectious diseases · 2025Article
- Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin-resistant tuberculosis.British journal of clinical pharmacology · 2025Article
- Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin-resistant tuberculosis.British journal of clinical pharmacology · 2025Article
- The effect of pregnancy on the population pharmacokinetics of levofloxacin in South Africans with rifampicin-resistant tuberculosis.Antimicrobial agents and chemotherapy · 2025Article
- Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis.Antimicrobial agents and chemotherapy · 2024Article
- Acceptability of levofloxacin dispersible and non-dispersible tablet formulations in children receiving TB preventive treatment.IJTLD open · 2024Article
- Holistic acceptability of an adult levofloxacin formulation in children and adolescents on a tuberculosis preventive treatment trial.PLOS global public health · 2024Article
- QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies.Antimicrobial agents and chemotherapy · 2023Observational
- Clinical standards for the dosing and management of TB drugs.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2022Article
- Treatment of Rifampicin-Resistant Tuberculosis Disease and Infection in Children: Key Updates, Challenges and Opportunities.Pathogens (Basel, Switzerland) · 2022Review
- A Review of Clinical Pharmacokinetic and Pharmacodynamic Relationships and Clinical Implications for Drugs Used to Treat Multi-drug Resistant Tuberculosis.European journal of drug metabolism and pharmacokinetics · 2020Review
- Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis.Antimicrobial agents and chemotherapy · 2020Article
- Pharmacokinetics of Levofloxacin in Children Treated for Exposure to Drug-Resistant Tuberculosis.Antimicrobial agents and chemotherapy · 2019Article
- Multidrug-resistant tuberculosis infection and disease in children: a review of new and repurposed drugs.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study characterized the pharmacokinetics of novel 100-mg levofloxacin dispersible tablets in 24 children aged <5 years who had household multidrug-resistant tuberculosus (MDR-TB) exposure. The current data were pooled with previously published data from children (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.